|
|
|
News 2011
| Siena, June 6th, 2011 |
|
| Press Release – Bayer Schering Pharma AG to support completion of Philogen’s clinical trials. >>Read more |
|
|
| |
| Chicago, USA, June 3th-7th, 2011 |
|
Philogen announces that it will have presentations by its Principal Investigators at the 2011 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, June3rd-7th. Accepted abstracts include:
- Darleukin (L19-IL2) in Metastatic Melanoma - A dose confirmation and signal generating study of the immunocytokine L19-IL2 in combination with dacarbazine in patients with metastatic melanoma
- Teleukin (F16-IL2) in Solid Tumors - Combination of the immunocytokine F16-Il2 with doxorubicin or paclitaxel in patients with solid tumors: results from two phase Ib trials
- Tenarad (F16-I131) in Hodgkin’s Disease - Preliminary evaluation of radioimmunotherapy with Tenarad, a I131 labeled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin’s disease (HD)
- Radretumab (L19-I131) in Brain Metastases from solid cancer - Preliminary evaluation of radioimmunotherapy with I131 labeled small immunoprotein targeted against the extra domain B of fibronectin in combination with whole brain radiation in patients with multiple brain metastases from solid tumors
>>Read More |
|
|
| |
| Siena, March 1st, 2011 |
|
| Philochem AG, the research unit of Philogen S.p.A., announces that it has entered a collaborative agreement with Pfizer Inc. in the field of cancer target discovery. |
|
|
| |
|
|
